Roche's approach to buying Illumina may have cost the Swiss drug development and diagnostic firm a chance at the San Diego-based next-generation sequencing firm, Illumina President and CEO Jay Flatley tells Bloomberg.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.